Filing Flows › Collegium Pharmaceutical (COLL) › Xtampza ER revenue
Collegium Pharmaceutical (COLL) Xtampza ER revenue by quarter
Collegium Pharmaceutical's Xtampza ER revenue was $45.8M in Q3 2026 (third quarter 2026), +2% from Q2 2026. Over the last 3 quarters it ranged from $45.0M (Q2 2026) to $50.8M (Q1 2026).
| Quarter | Xtampza ER revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $45.8M | +2% | — |
| Q2 2026 | $45.0M | -11% | — |
| Q1 2026 | $50.8M | — | — |
Q3 2026 at a glance
Collegium Pharmaceutical, Q3 2026: revenue $216M (+3% year over year), operating margin 13.3%, net earnings $21.8M, operating cash flow $86.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Collegium Pharmaceutical's Xtampza ER revenue?
Collegium Pharmaceutical's Xtampza ER revenue was $45.8M in Q3 2026 (third quarter 2026), +2% from Q2 2026.
How has Collegium Pharmaceutical's Xtampza ER revenue changed?
Over the last 3 quarters it ranged from $45.0M (Q2 2026) to $50.8M (Q1 2026).
Q3 2026 results → · How Collegium Pharmaceutical makes money →